The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

V.a

Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

Publications

Ustun C, Randall N, Podgaetz E, Amin K, Dincer HE

Severe dyspnoea in a patient with chronic myelogenous leukaemia on a tyrosine kinase inhibitor.

Thorax. 2015;70(7):701-4

Usküdar Teke H, Akay OM, Gören Şahin D, Karagülle M, Gündüz E, Andıç N

Pleural effusion: a rare side effect of nilotinib-a case report.

Case reports in medicine. 2014;2014:203939

Breccia M, Alimena G

Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors.

Leukemia research. 2013;37(6):713-20

Chakraborty K, Bossaer JB, Patel R, Krishnan K

Successful treatment of nilotinib-induced pleural effusion with prednisone.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2013;19(2):175-7